This is a Phase 1, open-label, multicenter study evaluating the safety, pharmacokinetic
profile, and preliminary efficacy of ABT-199 in combination with Bendamustine/Rituximab in
approximately 60 subjects with relapsed or refractory non-Hodgkin's lymphoma. This study will
evaluate the safety and pharmacokinetic profile of ABT-199 in approximately 60 subjects when
administered in combination with Bendamustine/Rituximab following a dose escalation scheme,
with the objective of defining the dose limiting toxicity and the maximum tolerated dose.